Stockscreener 앱 받기
0.7408
2.94%
-0.0224
시장 영업 전:
.70
-0.0408
-5.51%
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Sutro Biopharma (NASDAQ:STRO) Upgraded to Overweight at Piper Sandler - Defense World
Sutro Biopharma (STRO) Receives Upgrade to Overweight by Piper S - GuruFocus
Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target - MarketScreener
Sutro Biopharma (STRO) Receives Upgrade with Promising Drug Prospects | STRO Stock News - GuruFocus
Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Bank of America Corp DE Sells 22,894 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Analysts - Defense World
Piper Sandler Upgrades Sutro Biopharma (STRO) to Overweight | ST - GuruFocus
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Position Decreased by Two Sigma Investments LP - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLC - Defense World
ProShare Advisors LLC Boosts Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Nuveen Asset Management LLC Acquires 124,154 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma names Greg Chow as new CFO - Investing.com
Sutro Biopharma (STRO) Appoints New CFO Greg Chow | STRO Stock N - GuruFocus
Sutro Biopharma names Greg Chow as new CFO By Investing.com - Investing.com Canada
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer - The Manila Times
Sutro Biopharma Strengthens ADC Leadership: New CFO Brings $225M Capital Raising Track Record - Stock Titan
Two Sigma Advisers LP Has $1.01 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Northern Trust Corp Buys 14,492 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Buys 68,234 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes By Investing.com - Investing.com Nigeria
Sutro Biopharma’s SWOT analysis: stock shifts focus amid pipeline changes - Investing.com
Sutro Biopharma unveils best-in-class anti-tissue factor ADC - BioWorld MedTech
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $0.80 by Analysts at Bank of America - Defense World
Sutro Biopharma (STRO): Analyst Lowers Price Target by 20% | STR - GuruFocus
Bank of America Adjusts Sutro Biopharma (STRO) Price Target | ST - GuruFocus
Dimensional Fund Advisors LP Buys 156,139 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Reports Q1 2025 Earnings and Restructuring - TipRanks
Transcript : Sutro Biopharma, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Sutro Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Barclays PLC - Defense World
Sutro Biopharma Inc Reports Q1 2025 Revenue of $17.4M, Exceeding Estimates; EPS at -$0.91, Missing Projections - GuruFocus
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Sutro Biopharma earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | STRO Stock News - GuruFocus
Sutro Biopharma, Inc. Advances ADC Pipeline Focus with Promising Preclinical Results and Strategic Reprioritization - Nasdaq
Financial Metrics Check: Sutro Biopharma Inc (STRO)’s Ratios for Trailing Twelve Months - DWinneX
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Invesco Ltd. - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright - The AM Reporter
Sutro Biopharma to Participate in Upcoming Investor Conferences - The Manila Times
Leading ADC Developer Sutro Biopharma to Present at Citizens and BofA Healthcare Conferences in May - Stock Titan
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
Sutro Biopharma (NASDAQ:STRO) Earns “Neutral” Rating from HC Wainwright - Defense World
Taking the lead: Sutro Biopharma Inc (STRO) - Sete News
1.08%
2.14%
자본화:
|
볼륨(24시간):